ArticleThe Journal of international medical research2026
Therapeutic effect of N-acetylcysteine in severe or critical coronavirus disease 2019 pneumonia: A retrospective cohort study.
Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundSevere or critical coronavirus disease 2019 pneumonia is associated with a high mortality rate and considerable treatment cost. Although a few reports have shown that N-acetylcysteine may shorten recovery time in patients with severe acute respiratory syndrome coronavirus 2 infection, its effect on mortality or disease progression in patients with severe or critical coronavirus disease 2019 pneumonia has not been investigated. This study aimed to evaluate the effect of N-acetylcysteine on mortality or disease progression, hospital stay, and hospitalization costs in patients with severe or critical coronavirus disease 2019 pneumonia.MethodsThis single-center, retrospective cohort study included 221 patients with severe or critical coronavirus disease 2019 pneumonia who were hospitalized at the Department of Respiratory and Critical Care Medicine, Huashan Hospital from December 2022 to January 2023. After 1:1 propensity score matching, 176 patients were divided into two groups based on whether oral N-acetylcysteine was administered for at least 3 days. Binary logistic regression was used to analyze the effect of N-acetylcysteine on mortality or disease progression, whereas its effect on 28- or 90-day mortality was analyzed using Cox regression.ResultsBinary logistic regression analysis showed that N-acetylcysteine was associated with a reduced risk of the composite endpoint of mortality or disease progression during hospitalization (odds ratio = 0.288, 95% confidence interval: 0.147-0.793,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.